You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
DNQX disodium salt
Water-soluble form of DNQX (Cat. No. 0189). Selective non-NMDA receptor antagonist.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 296.1. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.38 mL||16.89 mL||33.77 mL|
|5 mM||0.68 mL||3.38 mL||6.75 mL|
|10 mM||0.34 mL||1.69 mL||3.38 mL|
|50 mM||0.07 mL||0.34 mL||0.68 mL|
References are publications that support the biological activity of the product.
Honore et al (1988) Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 241 701 PMID: 2899909
Watkins et al (1990) Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. TiPS 11 25 PMID: 2155495
If you know of a relevant reference for DNQX disodium salt, please let us know.
View Related Products by Product Action
Keywords: DNQX disodium salt, DNQX disodium salt supplier, Water-soluble, salt, Glutamate, Kainate, Receptors, iGluR, Ionotropic, AMPA, non-NMDA, 2312, Tocris Bioscience
8 Citations for DNQX disodium salt
Citations are publications that use Tocris products. Selected citations for DNQX disodium salt include:
Li et al (2019) TMEM16B regulates anxiety-related behavior and GABAergic neuronal signaling in the central lateral amygdala. Elife 8 PMID: 31482844
Loo et al (2019) Single-cell transcriptomic analysis of mouse neocortical development. Nat Commun 10 134 PMID: 30635555
Dilger et al (2015) Absence of plateau potentials in dLGN cells leads to a breakdown in retinogeniculate refinement. J Neurosci 35 3652 PMID: 25716863
Abrahao et al (2017) Ethanol-Sensitive Pacemaker Neurons in the Mouse External Globus Pallidus. Neuropsychopharmacology 42 1070 PMID: 27827370
Pan et al (2016) Postnatal development of the electrophysiological properties of somatostatin interneurons in the anterior cingulate cortex of mice. J Neurosci 6 28137 PMID: 27319800
Tseng et al (2015) Giant ankyrin-G stabilizes somatodendritic GABAergic synapses through opposing endocytosis of GABAA receptors. Sci Rep 112 1214 PMID: 25552561
Lindstrom et al (2010) Retinal input to efferent target amacrine cells in the avian retina. Proc Natl Acad Sci U S A 27 103 PMID: 20650017
Linnemann et al (2006) Transient change in GABA(A) receptor subunit mRNA expression in Lurcher cerebellar nuclei during Purkinje cell degeneration. Vis Neurosci 7 59 PMID: 16872511
Do you know of a great paper that uses DNQX disodium salt from Tocris? Please let us know.
Reviews for DNQX disodium salt
Average Rating: 5 (Based on 2 Reviews.)
Have you used DNQX disodium salt?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
DNQX (20 micromolar) blocked spontaneous excitatory postsynaptic currents in an ex-vivo slice preparation.
We delivered this drug intracranially in combination with AP5 to block glutamatergic transmission in the mouse VTA. Product was highly soluble and worked well and as described, producing a robust decrease in place preference behavior.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.